Kiran Mazumdar-Shaw shares with Catherine Jewell, her story of innovation and entrepreneurship; Her journey from brewing to creating Biocon, Asia's leading Biopharmaceutical Company.
By Kiran Mazumdar Shaw, CMD, Biocon The approval of our biosimilar Trastuzumab by the U.S. FDA is a vindication of our two-decade-long biologics-led pharmaceutical journey. We had invested ‘ahead of the curve’ in the promising future of targeted biologics at the turn of the millennium. At that time, we had anticipated some of the risks, [...]
Financial Chronicle: Big Interview: Biocon CMD Kiran Mazumdar-Shaw spoke to FC on a range of topics, including women as entrepreneurs, philanthropy, affordable healthcare, citizen activism etc. Here’s the full version of the interview. As a woman business leader, what are some of the challenges you have encountered in getting to the top and how were [...]
The last 70 years have been transformational for the Indian biotech industry, mirroring the nation’s own rapidly advancing economy and rising global status. We have successfully leveraged recombinant DNA technology to deliver biopharmaceuticals, vaccines, genetically engineered crops and enzymes. In doing so, we have created a notable bio-economy valued at $35 billion. We have embraced [...]
To download the complete article, visit: http://bit.ly/2ncVkXM
2016 was a landmark year for the biotechnology industry as it was for the first time that the revolutionary CRISPR-Cas9 gene-editing technique was used in humans. With more human trials involving CRISPR-Cas9 scheduled to be conducted, I believe 2017 will be the year when the technology’s potential to treat human diseases could receive strong clinical [...]
There are nearly half a billion diabetes patients in the world. The alarming growth in the global diabetes population is leading to a huge demand for effective therapies from pre/early diabetes to late-stage disease. Of the 100 million people who need insulin globally, however, only ‘one in two’ can manage and afford costs associated with [...]